Marshall Wace’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Marshall Wace’s Portfolio KNTE Stock Details KNTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-156,089	Closed	-$415K	–	3120
2024 Q1	$415K	Sell	156,089 -38,379	-20%	-$95K	﹤0.01%	2003
2023 Q4	$461K	Buy	194,468 +110,320	+131%	+$195K	﹤0.01%	1745
2023 Q3	$118K	Sell	84,148 -24,302	-22%	-$58.4K	﹤0.01%	2036
2023 Q2	$329K	Buy	+108,450	New	+$418K	﹤0.01%	2110
2023 Q1	–	Sell	-14,944	Closed	-$91.2K	–	3285
2022 Q4	$91.2K	Buy	14,944 +3,492	+30%	+$28.4K	﹤0.01%	2797
2022 Q3	$137K	Buy	+11,452	New	+$150K	﹤0.01%	3146

Marshall Wace's KNTE Position: Q2 2024 in Review

Marshall Wace sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2024, closing a stake of 156,089 shares — an estimated $415K sold.

Marshall Wace first reported a position in KNTE in Q3 2022 and held it in 6 quarters. The position peaked at $461K in Q4 2023. 0 funds tracked by Wall St. Rank hold KNTE as of Q2 2024.

Marshall Wace reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Marshall Wace sold 156,089 Kinnate Biopharma Inc. Common Stock shares in Q2 2024, an estimated $415K.
Marshall Wace first reported a position in Kinnate Biopharma Inc. Common Stock in Q3 2022 and held it in 6 quarters.
Marshall Wace's Kinnate Biopharma Inc. Common Stock position peaked at $461K in Q4 2023.
0 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2024.

Based on Marshall Wace's 13F filing for Q2 2024, filed 14 Aug 2024.